Search details
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38621400
3.
Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients.
Gastrointest Endosc
; 2024 Jan 23.
Article
in English
| MEDLINE | ID: mdl-38272276
4.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36990608
5.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-32955174
6.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Article
in English
| MEDLINE | ID: mdl-32343890
7.
FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
Radiology
; 307(3): e221180, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36853183
8.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Article
in English
| MEDLINE | ID: mdl-37880788
9.
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Histopathology
; 83(1): 91-103, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36999648
10.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36261050
11.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35131040
12.
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Prostate
; 82(9): 993-1002, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35435276
13.
Prostate cancer.
Lancet
; 398(10305): 1075-1090, 2021 09 18.
Article
in English
| MEDLINE | ID: mdl-34370973
14.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Article
in English
| MEDLINE | ID: mdl-34246347
15.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Article
in English
| MEDLINE | ID: mdl-33581798
16.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Article
in English
| MEDLINE | ID: mdl-31157964
17.
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Invest New Drugs
; 40(5): 1051-1065, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35635631
18.
Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone.
EMBO Rep
; 21(6): e50162, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32314873
19.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34246328
20.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33989557